130933-46-9

Upstream product

• 130933-88-9 ethyl 4-<4-(4-fluorophenyl)-1-piperazinyl>butyrate 
• 2252-63-3 1-(4-Fluorophenyl)piperazine 

Downstream Products

• 130933-86-7 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-(6aS,10aS,11S)-6,6a,7,8,9,10,10a,11-octahydro-dibenzo[b,e]oxepin-11-yl-butyramide 
• 1020000-51-4 C₂₉H₃₀FN₅O₂ 
• 1020000-89-8 C₂₉H₂₉F₂N₅O₂ 
• 1020000-69-4 C₂₉H₂₉F₂N₅O₂ 
• 130933-83-4 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-((4aR,5R,11aR)-7-methoxy-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl)-butyramide 
• 130953-92-3 N-((4aR,5R,11aR)-7-Chloro-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl)-4-[4-(4-fluoro-phenyl)-piperazin-1-yl]-butyramide 
• 130933-79-8 N-((4aR,5R,11aR)-7-Fluoro-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl)-4-[4-(4-fluoro-phenyl)-piperazin-1-yl]-butyramide 
• 130933-81-2 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-((4aR,5R,11aR)-7-methyl-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl)-butyramide 
• 130982-73-9 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-(4aR,5S,11aS)-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl-butyramide 
• 130933-61-8 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-(4aR,5S,11aR)-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl-butyramide 
• 130933-61-8 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-(4aS,5S,11aS)-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl-butyramide 
• 131063-06-4 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-N-(4aS,5S,11aR)-1,2,3,4,4a,5,11,11a-octahydro-10-thia-dibenzo[a,d]cyclohepten-5-yl-butyramide 

Relevant academic research and scientific papers

Novel quinazolinone derivatives as 5-HT7 receptor ligands

5-HT7 receptor antagonists generated antidepressant-like effects in animal model and the involvement of the 5-HT7 receptor in other pathophysiological mechanisms such as thermoregulation, learning and memory, and sleep has been highl

A New Class of Calcium Antagonists. Synthesis and Biological Activity of 11--6,6a,7,8,9,10,10a,11-octahydrodibenzothiepin Derivatives

A series of 11--6,6a,7,8,9,10,10a,11-octahydrodibenzothiepin derivatives were prepared and found to be structurally new class of calcium antagonists.The structure-activivty relationship studies indicated that the optimum was (6aR*,10aR*,11R*)-11-butyryl>amino>-6,6a,7,8,9,10,10a,11-octahydrodibenzothiepin (31, pA2 8.16), which was superior to diltiazem (pA2 7.42) in calcium antagonistic activity.Compound 31 showed antihypertensive activity in anesthetized rats, without a significant effect on the heart rate.It had also antianginal effects in vasopressin-induced ST-elevation testings in rats.These potencies of 31 were essentially equal to those of diltiazem.